HQL (abrdn Life Sciences Investors) Piotroski F-Score: 4 (As of Aug. 20, 2026) — Near Median

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

HQL abrdn Life Sciences Investors HQL
51 GF Score
Price $22.08
GF Value $62.01
Valuation Significantly Undervalued
! 5 Warning Signs
View Full Analysis

What is abrdn Life Sciences Investors Piotroski F-Score?

abrdn Life Sciences Investors HQL -2.60% 51 Piotroski F-Score is 4 as of Aug. 20, 2026, which is at its 10-year median of 4.00. GuruFocus rates HQL with a GF Score™ of 51/100 and a GF Value™ of $62.01 (Significantly Undervalued). The stock has 5 warning signs investors should review. Among 1,593 Asset Management companies, abrdn Life Sciences Investors ranks worse than 58.44% on this metric.

The zones of discrimination were as such:

Good or high score = 7, 8, 9
Bad or low score = 0, 1, 2, 3

abrdn Life Sciences Investors has an F-score of 4 indicating the company's financial situation is typical for a stable company.

The historical rank and industry rank for abrdn Life Sciences Investors's Piotroski F-Score or its related term are showing as below:

HQL' s Piotroski F-Score Range Over the Past 10 Years
Min: 2   Med: 4   Max: 6
Current: 4

During the past 9 years, the highest Piotroski F-Score of abrdn Life Sciences Investors was 6. The lowest was 2. And the median was 4.

abrdn Life Sciences Investors  (NYSE:HQL) Piotroski F-Score Explanation

The developer of the system is Joseph D. Piotroski is relatively unknown accounting professor who shuns publicity and rarely gives interviews.

He graduated from the University of Illinois with a B.S. in accounting in 1989, received an M.B.A. from Indiana University in 1994. Five years later, in 1999, after earning a Ph.D. in accounting from the University of Michigan, he became an associate professor of accounting at the University of Chicago.

In 2000, he wrote a research paper called "Value Investing: The Use of Historical Financial Statement Information to Separate Winners from Losers" (pdf).

He wanted to see if he can develop a system (using a simple nine-point scoring system) that can increase the returns of a strategy of investing in low price to book (referred to in the paper as high book to market) value companies.

What he found was something that exceeded his most optimistic expectations.

Buying only those companies that scored highest (8 or 9) on his nine-point scale, or F-Score as he called it, over the 20 year period from 1976 to 1996 led to an average out-performance over the market of 13.4%.

Even more impressive were the results of a strategy of investing in the highest F-Score companies (8 or 9) and shorting companies with the lowest F-Score (0 or 1).

Over the same period from 1976 to 1996 (20 years) this strategy led to an average yearly return of 23%, substantially outperforming the average S&P 500 index return of 15.83% over the same period.


abrdn Life Sciences Investors Piotroski F-Score Related Terms


abrdn Life Sciences Investors Piotroski F-Score Historical Data

* Premium members only.

The historical data trend for abrdn Life Sciences Investors's Piotroski F-Score can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

abrdn Life Sciences Investors Piotroski F-Score Chart

abrdn Life Sciences Investors Annual Data
Trend Sep17 Sep18 Sep19 Sep20 Sep21 Sep22 Sep23 Sep24 Sep25
Piotroski F-Score
Get a 7-Day Free Trial Premium Member Only 2.00 3.00 5.00 6.00 4.00

abrdn Life Sciences Investors Semi-Annual Data
Sep17 Mar18 Sep18 Mar19 Sep19 Mar20 Sep20 Mar21 Sep21 Mar22 Sep22 Mar23 Sep23 Mar24 Sep24 Mar25 Sep25 Mar26
Piotroski F-Score Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 6.00 0.00 4.00 0.00

HQL vs IIM, NOAH, FAX: Piotroski F-Score Comparison

For the Asset Management subindustry, abrdn Life Sciences Investors's Piotroski F-Score, along with its competitors' market caps and Piotroski F-Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


abrdn Life Sciences Investors Piotroski F-Score vs Asset Management Industry

For the Asset Management industry and Financial Services sector, abrdn Life Sciences Investors's Piotroski F-Score distribution charts can be found below:

* The bar in red indicates where abrdn Life Sciences Investors's Piotroski F-Score falls into.


HQL
51GF Score
abrdn Life Sciences Investors HQL
Piotroski F-Score is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

How is the Piotroski F-Score calculated?

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

This Year (Sep25) TTM:Last Year (Sep24) TTM:
Net Income was $85.6 Mil.
Cash Flow from Operations was $31.7 Mil.
Revenue was $86.4 Mil.
Average Total Assets from the begining of this year (Sep24)
to the end of this year (Sep25) was (460.583 + 515.382) / 2 = $487.9825 Mil.
Total Assets at the begining of this year (Sep24) was $460.6 Mil.
Long-Term Debt & Capital Lease Obligation was $0.0 Mil.
Total Assets was $515.4 Mil.
Total Liabilities was $1.7 Mil.
Net Income was $85.3 Mil.

Revenue was $86.7 Mil.
Average Total Assets from the begining of last year (Sep23)
to the end of last year (Sep24) was (402.6 + 460.583) / 2 = $431.5915 Mil.
Total Assets at the begining of last year (Sep23) was $402.6 Mil.
Long-Term Debt & Capital Lease Obligation was $0.0 Mil.
Total Assets was $460.6 Mil.
Total Liabilities was $0.9 Mil.

*Note: If the latest quarterly/semi-annual/annual total assets data is 0, then we will use previous quarterly/semi-annual/annual data for all the items in the balance sheet.

Profitability

Question 1. Return on Assets (ROA)

Net income before extraordinary items for the year divided by Total Assets at the beginning of the year.

Score 1 if positive, 0 if negative.

abrdn Life Sciences Investors's current Net Income (TTM) was 85.6. ==> Positive ==> Score 1.

Question 2. Cash Flow Return on Assets (CFROA)

Net cash flow from operating activities (operating cash flow) divided by Total Assets at the beginning of the year.

Score 1 if positive, 0 if negative.

abrdn Life Sciences Investors's current Cash Flow from Operations (TTM) was 31.7. ==> Positive ==> Score 1.

Question 3. Change in Return on Assets

Compare this year's return on assets (1) to last year's return on assets.

Score 1 if it's higher, 0 if it's lower.

ROA (This Year)=Net Income/Total Assets (Sep24)
=85.594/460.583
=0.18583838

ROA (Last Year)=Net Income/Total Assets (Sep23)
=85.296/402.6
=0.21186289

abrdn Life Sciences Investors's return on assets of this year was 0.18583838. abrdn Life Sciences Investors's return on assets of last year was 0.21186289. ==> Last year is higher ==> Score 0.

Question 4. Quality of Earnings (Accrual)

Compare Cash flow return on assets (2) to return on assets (1)

Score 1 if CFROA > ROA, 0 if CFROA <= ROA.

abrdn Life Sciences Investors's current Net Income (TTM) was 85.6. abrdn Life Sciences Investors's current Cash Flow from Operations (TTM) was 31.7. ==> 31.7 <= 85.6 ==> CFROA <= ROA ==> Score 0.

Funding

Question 5. Change in Gearing or Leverage

Compare this year's gearing (long-term debt divided by average total assets) to last year's gearing.

Score 0 if this year's gearing is higher, 1 otherwise.

Gearing (This Year: Sep25)=Long-Term Debt & Capital Lease Obligation/Average Total Assets from Sep24 to Sep25
=0/487.9825
=0

Gearing (Last Year: Sep24)=Long-Term Debt & Capital Lease Obligation/Average Total Assets from Sep23 to Sep24
=0/431.5915
=0

abrdn Life Sciences Investors's gearing of this year was 0. abrdn Life Sciences Investors's gearing of last year was 0. ==> This year is lower or equal to last year. ==> Score 1.

Question 6. Change in Working Capital (Liquidity)

Compare this year's current ratio (current assets divided by current liabilities) to last year's current ratio.

Score 1 if this year's current ratio is higher, 0 if it's lower

* Note that for banks and insurance companies, there's no Total Current Assets and Total Current Liabilities reported. Thus, we use Total Assets and Total Liabilities to calculate current ratio for banks and insurance companies.

Current Ratio (This Year: Sep25)=Total Assets/Total Liabilities
=515.382/1.726
=298.599073

Current Ratio (Last Year: Sep24)=Total Assets/Total Liabilities
=460.583/0.889
=518.09111361

abrdn Life Sciences Investors's current ratio of this year was 298.599073. abrdn Life Sciences Investors's current ratio of last year was 518.09111361. ==> Last year's current ratio is higher ==> Score 0.

Question 7. Change in Shares in Issue

Compare the number of shares in issue this year, to the number in issue last year.

Score 0 if there is larger number of shares in issue this year, 1 otherwise.

abrdn Life Sciences Investors's number of shares in issue this year was 30.679. abrdn Life Sciences Investors's number of shares in issue last year was 28.058. ==> There is larger number of shares in issue this year. ==> Score 0.

Efficiency

Question 8. Change in Gross Margin

Compare this year's gross margin (Gross Profit divided by sales) to last year's.

Score 1 if this year's gross margin is higher, 0 if it's lower.

* Note that for banks and insurance companies, there's no Gross Profit reported. Thus, we use net income instead of gross profit and calculate Net Margin for this score.

Net Margin (This Year: TTM)=Net Income/Revenue
=85.594/86.386
=0.99083185

Net Margin (Last Year: TTM)=Net Income/Revenue
=85.296/86.685
=0.98397647

abrdn Life Sciences Investors's net margin of this year was 0.99083185. abrdn Life Sciences Investors's net margin of last year was 0.98397647. ==> This year's net margin is higher. ==> Score 1.

Question 9. Change in asset turnover

Compare this year's asset turnover (total sales for the year divided by total assets at the beginning of the year) to last year's asset turnover ratio.

Score 1 if this year's asset turnover ratio is higher, 0 if it's lower

Asset Turnover (This Year)=Revenue/Total Assets at the Beginning of This Year (Sep24)
=86.386/460.583
=0.18755794

Asset Turnover (Last Year)=Revenue/Total Assets at the Beginning of Last Year (Sep23)
=86.685/402.6
=0.21531297

abrdn Life Sciences Investors's asset turnover of this year was 0.18755794. abrdn Life Sciences Investors's asset turnover of last year was 0.21531297. ==> Last year's asset turnover is higher ==> Score 0.

Evaluation

Piotroski F-Score= Que. 1+ Que. 2+ Que. 3+Que. 4+Que. 5+Que. 6+Que. 7+Que. 8+Que. 9
=1+1+0+0+1+0+0+1+0
=4

Good or high score = 7, 8, 9
Bad or low score = 0, 1, 2, 3

abrdn Life Sciences Investors has an F-score of 4 indicating the company's financial situation is typical for a stable company.

Frequently Asked Questions Learn more about Piotroski F-Score →
What does a Piotroski F-Score of 4 mean?
abrdn Life Sciences Investors (HQL) has a Piotroski F-Score of 4 as of Aug. 20, 2026. The Piotroski F-score grades a company's business operating strength from 0-9. View historical data on abrdn Life Sciences Investors and its competitors. This is near median its historical median of 4.00. Over the past decade, abrdn Life Sciences Investors' Piotroski F-Score has ranged from 2.00 to 6.00. According to the industry distribution chart, abrdn Life Sciences Investors ranks #931 out of 1593 companies in the Asset Management industry, placing it in the top 58.4%.
Is abrdn Life Sciences Investors' Piotroski F-Score too high?
abrdn Life Sciences Investors' current Piotroski F-Score of 4 is near median its 10-year median of 4.00. Over the past 10 years, this metric has ranged from a low of 2.00 to a high of 6.00. The Asset Management industry median Piotroski F-Score is 5.00. abrdn Life Sciences Investors' value of 4 is 20% below this industry median. Based on the distribution chart, abrdn Life Sciences Investors ranks #931 out of 1593 companies in the Asset Management industry, which is below the industry midpoint. Overall, abrdn Life Sciences Investors has a GF Score™ of 51/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does abrdn Life Sciences Investors' Piotroski F-Score compare to IIM and NOAH?
According to the Asset Management industry distribution chart, abrdn Life Sciences Investors ranks #931 out of 1593 companies for Piotroski F-Score. This places abrdn Life Sciences Investors in the lower half of its industry. The industry median Piotroski F-Score is 5.00. abrdn Life Sciences Investors' value of 4 is 20% below this benchmark. Historically, abrdn Life Sciences Investors' own Piotroski F-Score has ranged from 2.00 to 6.00 over the past decade. While the company's 10-year median is 4.00 vs. the industry median of 5.00, abrdn Life Sciences Investors has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Piotroski F-Score for an Asset Management company?
The median Piotroski F-Score among Asset Management companies is 5.00, based on 1,593 companies in the industry. Companies in the top quartile (top 25%) have a Piotroski F-Score significantly above this median, while those in the bottom quartile fall well below. However, Piotroski F-Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. abrdn Life Sciences Investors's current Piotroski F-Score of 4 is 20% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Piotroski F-Score mean?
A high Piotroski F-Score can signal that a stock is expensive relative to its fundamentals. The Piotroski F-score grades a company's business operating strength from 0-9. View historical data on abrdn Life Sciences Investors and its competitors. For the Asset Management industry, the median Piotroski F-Score is 5.00 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. abrdn Life Sciences Investors's current Piotroski F-Score is 4, which is near median its own 10-year median of 4.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is abrdn Life Sciences Investors stock overvalued right now?
Based on GuruFocus' analysis, abrdn Life Sciences Investors (HQL) is currently considered Significantly Undervalued. The stock's GF Value™ is $62.01, compared to a current price of $22.08 — trading 64.4% below its estimated fair value. The current Piotroski F-Score is 4, which is near median its 10-year median of 4.00 and 20% below the Asset Management industry median of 5.00. abrdn Life Sciences Investors' overall GF Score™ is 51/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Piotroski F-Score calculated?
Piotroski F-Score is calculated from a company's financial statements. For abrdn Life Sciences Investors (HQL), the current Piotroski F-Score is 4 as of Aug. 20, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is abrdn Life Sciences Investors (HQL) Overvalued in 2026?

Based on GuruFocus' analysis, abrdn Life Sciences Investors stock appears to be undervalued. The current stock price of $22.08 is trading 64.4% below its estimated GF Value™ of $62.01. GuruFocus considers abrdn Life Sciences Investors to be Significantly Undervalued.

Key valuation signals for HQL:

  • Piotroski F-Score: 4 (near median its 10-year median of 4.00)
  • GF Value™: $62.01 vs. price of $22.08 (64.4% below fair value)
  • GF Score™: 51/100 with 5 warning signs
  • Industry Position: 20% below the Asset Management median (#931 of 1593)

No single metric tells the full story. See the HQL stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


abrdn Life Sciences Investors Business Description

Address 1900 Market Street, Suite 200, Philadelphia, PA, USA, 19103
abrdn Life Sciences Investors operates as a non-diversified closed-end management investment company. Its investment objective is to seek long-term capital appreciation by investing mainly in securities of life sciences companies. It invests in securities of public and private companies that are believed by the Fund's Investment Adviser to have the potential for above-average growth.
51GF Score

Get the complete analysis for HQL

Piotroski F-Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$22.08
Price
$62.01
GF Value